Understand more about the Hyperion Imaging System.Learn More
The Hyperion™ Imaging System enables comprehensive analysis of cellular phenotypes and their interrelationships using Imaging Mass Cytometry™. Bringing together high-parameter CyTOF® technology with imaging capability, the Hyperion Imaging System enables you to visualize 4 to 37 protein markers in the spatial context of the tissue microenvironment.
Hear what researchers are saying about Imaging Mass Cytometry and the Hyperion Imaging System:
Complete the form below to stay up to date on the new Hyperion™ Imaging System antibodies, protocols and other developments.
A complete system
The Hyperion Imaging System is accompanied by a pathologist-verified Maxpar® imaging antibody portfolio, a software suite for image acquisition and data analysis and experienced Fluidigm service and support. Delivering a comprehensive view from one scan, the Hyperion Imaging System can enable you to deeply profile precious formalin-fixed paraffin-embedded (FFPE) or frozen tissues at subcellular resolution to power your next breakthrough.
A simple four-step workflow
The Imaging Mass Cytometry workflow enables deep profiling of standard FFPE or frozen tissue sections and of fixed cells deposited on glass microscope slides using the Hyperion Imaging System.
A new standard in high-multiplex protein detection
CyTOF technology offers a new standard for multiplex protein detection. The metals used to tag Maxpar antibodies have spectra based on mass and are detected as discrete peaks of similar intensity for similar protein expression level. This enables the routine use of many more metal tags in multiplex experiments without signal overlap, as compared to fluorescent dyes.
Protein biomarkers in human lung tissue are visualized at subcellular resolution following precise metal-tag capture from a human lung FFPE tissue sample and detection at 1 Da spectral resolution using proven CyTOF technology. Markers include alpha-smooth muscle action (141PR), high-molecular-weight keratin (144Nd), CD31 (145Nd), beta-catenin (147Sm), vimentin (143Nd), Ki-67 (168Er), CD34 (158Gd), CD3 (170Er), histone H3 (176Yb) and collagen I (169Tm).
Learn more about the use of Imaging Mass Cytometry applications that use a staining method that follows a workflow similar to traditional IF staining. The method generates comparable results while eliminating issues such as autofluorescence and spectral overlap.
“Through the ability of looking at 35 different antigens in a tissue section, their relationship to each other, we can really get new insights about cell heterogeneity—cell interactions—that we weren’t able to even approach before.”
Klaus Kaestner, PhD, MS
Thomas and Evelyn Suor Butterworth Professor in Genetics
University of Pennsylvania Perelman School of Medicine
Simplify multiplex panel design with pathologist-verified Maxpar antibodies
Metal-tagged pathologist-verified Maxpar antibodies for Imaging Mass Cytometry are designed and optimized for use with the Hyperion Imaging System. These antibodies can be combined using a protocol that provides a common antigen retrieval step to simplify panel design for use with FFPE human tissue sections. Flexibly customize panels using your own antibodies with Maxpar labeling kits or custom conjugation options.
Simultaneously interrogate multiple protein markers—all from a single scan
The Hyperion Imaging System enables deep profiling of precious samples in a single workflow, thereby eliminating the need for serial sections or sequential staining.
CyTOF technology offers a new standard for high-multiplex protein detection. In contrast to fluorescence spectra which have broad peaks that can result in signal overlap, metal tag spectra are based on mass. Because of the sensitivity of mass cytometry, even neighboring isotopes can be readily resolved. This separation enables the routine use of many more metal tags in multiplex experiments without signal overlap, as compared to fluorescent dyes.
Visualize spatial context of multiplex data in minutes
The MCD™ Viewer software that accompanies the Hyperion Imaging System precisely converts the scanned cells and tissues into TIFF images of publication quality. Each image can be spectrally separated to display the expression of each protein. Data for each region of interest can be exported for third-party analysis on software such as histoCAT™.
“Now that we can measure so many markers simultaneously, for the first time we have the ability to comprehensively study cell types and their signaling and functional state in normal tissue and especially in tumors, and also how they are spatially arranged.”
Bernd Bodenmiller, PhD
Assistant Professor of Institute of Molecular Life Sciences
University of Zurich
histoCAT™ software for computational Imaging Mass Cytometry™ analysis
histoCAT software is an innovative computational Imaging Mass Cytometry™ analysis toolbox that enables comprehensive analysis of cellular phenotypes and their interrelationships within the spatial context of the tissue microenvironment. Developed in the laboratory of Bernd Bodenmiller at the University of Zurich, histoCAT includes novel algorithms to identify the relationships and “social networks” between cells in healthy and disease states and across experimental cohorts. Under the agreement with the University of Zurich, Fluidigm obtained rights to globally distribute histoCAT along with the Hyperion™ Imaging System.
Maximize system performance with Fluidigm service, support and training
Boost productivity, control costs and minimize downtime with service plan options that are attractively priced and include regularly scheduled maintenance visits to ensure that your Hyperion Imaging System is kept in peak operating condition.
Fluidigm Field Application Specialists provide you with a selection of training programs to help you get started so you can begin asking new questions in your own research with the Hyperion Imaging System.
Watch the Future of Imaging launch event
Learn about Imaging Mass Cytometry and see the new Hyperion Imaging System unveiled in this recorded event, with presentations by Fluidigm CEO Chris Linthwaite and leading scientific researchers on Tuesday, October 24, 2017.